

FOI 2545

25th July 2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

Response: Eight

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

Response: Eight

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone):

Response: Two

R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone):

Response: Two

Pola-BR (polatuzumab vedotin with rituximab and bendamustine):

Response: One

Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone):

Response: Four

R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate):

Response: None

R-IVAC (rituximab, ifosfamide, etoposide and cytarabine):

Response: None

Axicabtagene ciloleucel (Yescarta):

Response: None

Tisagenlecleucel:

Response: None

Epcoritamab:

Response: None

Loncastuximab tesirine:

Response: None

Glofitamab:

Response: One

Any other SACT: R- GCVP:

Response: Three

R- ICE:

Response: One

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Response: This Response: This information is not held by the Trust as stem cell transplant or bone marrow treatment is provided by Belfast Health & Social Care Trust. You may wish to redirect this part of your request to publicliaison@belfasttrust.hscni.net

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

Axicabtagene ciloleucel (Yescarta):

Response: None

Tisagenlecleucel:

Response: None

Pola-BR (polatuzumab vedotin with rituximab and bendamustine):

Response: One

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Response: This information is not held by the Trust as stem cell transplant or bone marrow treatment is provided by Belfast Health & Social Care Trust. You may wish to redirect this part of your request to publicliaison@belfasttrust.hscni.net

Any other treatments:

Response: None

Q4. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

CAR-T Therapy (E.g. Axicabtagene ciloleucel)

Response: None

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Response: None

Any other treatment

Response: None

Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)?

Response: No

If so, can you please provide the name of each trial along with the number of patients taking part or enrolling?

Response: Not applicable

Email: foi.team@southerntrust.hscni.net